CRDL — Cardiol Therapeutics Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1702123 ·
Last close
$1.01
Market Cap
$116.42M
52W High
$1.71
52W Low
$0.96
ADV30
374,378
Next earnings
2026-05-14
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -9,706,794 | -10,818,589 | 31,406,607 | 27,673,191 | 7,203,302 |
| Dec 2025 | 0 | — | -8,030,975 | -7,212,569 | 23,619,933 | 21,416,684 | 5,742,215 |
| Sep 2025 | 0 | — | -10,180,100 | -9,964,281 | 12,947,801 | 11,622,408 | 3,386,926 |
| Jun 2025 | 0 | — | -7,676,158 | -8,354,371 | 19,937,699 | 18,195,052 | 8,129,824 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-23,854,650
Investing CF
$-24,484
Financing CF
$15,539,830
CapEx
$-24,484
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.50
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-213,072,975
Inventory
—
Receivables
$226,195
ST Investments
—
EBIT TTM
$-34,316,296
Pretax Income TTM
$-33,818,874
Interest Exp TTM
—
Analysts
4
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -34,316,296 | -33,818,874 | 23,619,933 | 5,742,215 | — | -23,854,650 |
| Dec 2024 | 0 | -40,276,651 | -36,677,299 | 31,863,751 | 7,135,268 | — | -25,060,867 |
| Dec 2023 | 0 | -29,785,504 | -28,128,292 | 36,700,508 | 8,454,001 | — | -25,180,441 |
| Dec 2022 | 0 | -41,335,878 | -30,930,647 | 62,028,518 | 9,826,930 | — | -27,220,345 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.20
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BDTX | Black Diamond Therapeutics, Inc. | $109.45M | $1.91 | — |
| ENGN | enGene Therapeutics Inc. | $127.28M | $1.90 | — |
| KLRS | Kalaris Therapeutics, Inc. | $105.64M | $4.44 | — |
| VXRT | Vaxart, Inc. | $132.16M | $0.55 | — |
| CGTX | COGNITION THERAPEUTICS INC | $97.55M | $1.09 | — |
News headlines (Yahoo Finance, 1h cache)
Cardiol Therapeutics to Participate in Fireside Chat at B. Riley Securities Mind, Muscle & Vision Summit
2026-07-09 11:27 · Yahoo
Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders
2026-06-25 11:27 · Yahoo
Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on June 24th at 4:30 p.m. EDT
2026-06-23 11:27 · Yahoo
Here's Why We're Watching Cardiol Therapeutics' (TSE:CRDL) Cash Burn Situation
2026-05-15 16:22 · Yahoo
Cardiol Therapeutics to Participate in Fireside Chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ
2026-05-14 11:27 · Yahoo
Cardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association
2026-05-07 11:27 · Yahoo
Cardiol Therapeutics Up In US Premarket As Expands Phase 3 Maveric Trial to Include 7 More Clinical Centers in the U.S.
2026-04-28 12:07 · Yahoo
Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program
2026-04-28 11:27 · Yahoo
Cardiol Therapeutics CEO: Phase III MAVERIC Nears Full Enrollment as CardiolRx Shows Myocarditis Promise
2026-04-15 10:15 · Yahoo
Cardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with Barchart
2026-04-14 11:27 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.